Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis - Summary - MDSpire

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

  • By

  • Caroline Kellogg

  • Elena Badillo Goicoechea

  • David D. Kim

  • Shadi Yaghi

  • Seemant Chaturvedi

  • Rachel Mehendale

  • Karen Orjuela

  • Tareq Kass-Hout

  • Rami Z. Morsi

  • Jacqueline Morales

  • Eesha Singh

  • Aditya Jhaveri

  • Shyam Prabhakaran

  • Matthew M. Smith

  • James R. Brorson

  • Samiksha Golani

  • Sofia Mazuera

  • Rachael Kang

  • Ali Eltatawy

  • Jessica Pillajo

  • James E. Siegler

  • May 5, 2026

  • 0 min

Share

Objective:

To evaluate the cost-effectiveness of PCSK9 inhibitors (PCSK9i) for secondary stroke prevention in patients with recent ischemic stroke due to high-grade intracranial atherosclerosis, specifically focusing on their impact on recurrent stroke rates.

Key Findings:
  • PCSK9i therapy could significantly reduce recurrent ischemic strokes in patients with high-grade intracranial atherosclerosis, with varying incremental cost-effectiveness ratios (ICERs) that highlight the importance of willingness-to-pay (WTP) thresholds.
Interpretation:

PCSK9 inhibitors may provide a cost-effective strategy for reducing recurrent strokes in high-risk patients, but their high costs and the need for further validation could limit widespread adoption.

Limitations:
  • Limited direct experimental evidence for PCSK9i effects on recurrent stroke in the specific patient population, and the analysis relies on theoretical models and assumptions regarding LDL reduction and stroke risk, which may not be generalizable.
Conclusion:

While PCSK9 inhibitors show promise in improving outcomes for patients with intracranial atherosclerosis, further studies are needed to validate their cost-effectiveness in real-world settings, emphasizing the necessity for practical evidence.

Original Source(s)

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

  • by Caroline Kellogg, Elena Badillo Goicoechea, David D. Kim, Shadi Yaghi, Seemant Chaturvedi, Rachel Mehendale, Karen Orjuela, Tareq Kass-Hout, Rami Z. Morsi, Jacqueline Morales, Eesha Singh, Aditya Jhaveri, Shyam Prabhakaran, Matthew M. Smith, James R. Brorson, Samiksha Golani, Sofia Mazuera, Rachael Kang, Ali Eltatawy, Jessica Pillajo, James E. Siegler

  • May 5, 2026

Related Content

Exploring person-centredness in technology-based gait rehabilitation after stroke: A scoping review framework analysis

Cardiometabolic index and modified cardiometabolic index are associated with early neurological deterioration in patients with acute ischemic stroke

Assessing the Effectiveness of the RACE Score in Distinguishing Stroke from Stroke Mimics in Emergency Department Settings